Walid Fazeli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Walid Fazeli has a total of 187 co-authors. Here are the top co-authors by number of shared publications:
- Rikke Steensbjerre MĂžller
Department of Epilepsy Genetics and Personalized Medicine, Member of ERN EpiCARE, Danish Epilepsy Centre, Dianalund, Denmark, Denmark
6 shared publications - Daniel Bamborschke
Department of Neuropediatrics, University Hospital Bonn, University of Bonn, member of ERN-EpiCARE, Germany
3 shared publications Friederike Körber
Department of Radiology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
3 shared publications- Markus Wolff
Swiss Epilepsy Center Klinik Lengg Zurich Switzerland
3 shared publications Abubakar Moawia
Department of Pediatrics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
2 shared publications- Afshin Saffari
Movement Disorders Program, Department of Neurology and F.M. Kirby Neurobiology Center, Boston Children's Hospital, Harvard Medical School, Boston, MA; Division of Child Neurology and Metabolic Medicine, Centre for Pediatric and Adolescent Medicine, University Hospital Heidelberg, Heidelberg, Germany
2 shared publications
Latest Publications
- 13 October 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107  (7) , e218541
Neuroradiologic Findings in Patients With S CN2A Disease
Background and ObjectivesSCN2A disease spans a broad clinical spectrum from self-limited (familial) neonatal-infantile epilepsy to severe developmental and epileptic encephalopathies. Systematic ch...
- 13 October 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107  (7) , e218541
Neuroradiologic Findings in Patients With S CN2A Disease
Background and ObjectivesSCN2A disease spans a broad clinical spectrum from self-limited (familial) neonatal-infantile epilepsy to severe developmental and epileptic encephalopathies. Systematic ch...
- Open Access
Mechanisms of SCN2A loss of function do not predict presence or phenotype of epilepsy
Objective: SCN2A lossâofâfunction (LoF) variants are associated with epilepsy (onset age â„ 3 months), intellectual disability (ID), and autism spectrum disorder (ASD). Despite numerous identified variants and the description of phenotypic subgroups, relationships between Na v 1.2 channel dysfunction and clinical phenotypes remain unclear. This study examined how distinct LoF mechanisms relate to phenotypic outcomes. Methods: Wholeâcell patchâclamp electrophysiology was used to characterize 15 presumed LoF SCN2A variants. Mechanismâphenotype correlations were assessed in 33 patients with these variants (six recurrent) and 41 patients with 15 previously characterized LoF variants (four recurrent). Phenotypic subgroups were categorized as later onset epilepsyâmidinfancy (onset between 3 and 18 months), later onset epilepsyâchildhood (onset after 18 months), ID/ASD without epilepsy, and âotherâ for unclassified cases. Results: Of the 15 electrophysiologically characterized SCN2A variants, 11 caused total Na v 1.2 LoF, three caused partial LoF, and one showed mixed LoF and gainâofâfunction (GoF) effects. Among previously published variants, seven showed total LoF, five partial LoF, and two mixed LoF/GoF, and one was undetermined. Across both cohorts, seven of 10 recurrent variants (70%) were associated with multiple phenotypic subgroups. Partial or total Na v 1.2 LoF variants were identified in all subgroups. Notably, a midinfancy epilepsy phenotype was observed in 22 of 24 individuals (92%) carrying a mixed LoF variant, with phenotype data unavailable for seven additional individuals. A novel LoFâassociated phenotypeâepisodic ataxia with or without developmental delay or IDâwas identified in five of six individuals with the L1650P variant. Although episodic ataxia has been previously associated with GoF variants in SCN2A , this is the first reported instance in individuals with a confirmed LoF variant. Significance: Distinct SCN2A LoF phenotypes cannot be reliably linked to specific biophysical mechanisms, as both total and partial Na v 1.2 LoF occurs across diverse phenotypes. For efficient personalized treatment, it is crucial not to rely solely on clinical phenotype to predict the underlying LoF mechanism.
Open AccessMechanisms of SCN2A loss of function do not predict presence or phenotype of epilepsy
Objective: SCN2A lossâofâfunction (LoF) variants are associated with epilepsy (onset age â„ 3 months), intellectual disability (ID), and autism spectrum disorder (ASD). Despite numerous identified variants and the description of phenotypic subgroups, relationships between Na v 1.2 channel dysfunction and clinical phenotypes remain unclear. This study examined how distinct LoF mechanisms relate to phenotypic outcomes. Methods: Wholeâcell patchâclamp electrophysiology was used to characterize 15 presumed LoF SCN2A variants. Mechanismâphenotype correlations were assessed in 33 patients with these variants (six recurrent) and 41 patients with 15 previously characterized LoF variants (four recurrent). Phenotypic subgroups were categorized as later onset epilepsyâmidinfancy (onset between 3 and 18 months), later onset epilepsyâchildhood (onset after 18 months), ID/ASD without epilepsy, and âotherâ for unclassified cases. Results: Of the 15 electrophysiologically characterized SCN2A variants, 11 caused total Na v 1.2 LoF, three caused partial LoF, and one showed mixed LoF and gainâofâfunction (GoF) effects. Among previously published variants, seven showed total LoF, five partial LoF, and two mixed LoF/GoF, and one was undetermined. Across both cohorts, seven of 10 recurrent variants (70%) were associated with multiple phenotypic subgroups. Partial or total Na v 1.2 LoF variants were identified in all subgroups. Notably, a midinfancy epilepsy phenotype was observed in 22 of 24 individuals (92%) carrying a mixed LoF variant, with phenotype data unavailable for seven additional individuals. A novel LoFâassociated phenotypeâepisodic ataxia with or without developmental delay or IDâwas identified in five of six individuals with the L1650P variant. Although episodic ataxia has been previously associated with GoF variants in SCN2A , this is the first reported instance in individuals with a confirmed LoF variant. Significance: Distinct SCN2A LoF phenotypes cannot be reliably linked to specific biophysical mechanisms, as both total and partial Na v 1.2 LoF occurs across diverse phenotypes. For efficient personalized treatment, it is crucial not to rely solely on clinical phenotype to predict the underlying LoF mechanism.
- Open Access
- 22 January 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 176, 110914
Caregiversâ experiences and expectations regarding seizure monitoring â A survey-based study
- 22 January 2026
- Published by Elsevier in Epilepsy & Behavior
- Vol. 176, 110914
Open AccessCaregiversâ experiences and expectations regarding seizure monitoring â A survey-based study
- Open Access
Early postnatal CA3 hyperexcitability drives hippocampal development and epileptogenesis in SCN2A developmental and epileptic encephalopathy
Developmental and epileptic encephalopathies caused by pathogenic variants in SCN2A ( SCN2A -DEE), encoding the voltage-gated sodium channel Na v 1.2, present with early-life seizures, developmental delay, and increased mortality. Using a novel Scn2a p.A263V gain-of-function (GOF) mouse model, we demonstrate gene-dose and background-dependent phenotypes ranging from self-limited neonatal seizures to chronic epilepsy with high mortality. In vivo electrophysiology revealed hippocampal seizures as early as postnatal day 2.5, with CA3-driven gamma oscillations preceding seizure onset. CA3 and CA1 pyramidal neurons exhibited transient hyperexcitability during early postnatal development, resolving by P24-30. Single-cell RNA sequencing uncovered gene dose-dependent accelerated maturation of hippocampal networks, peaking at P7, alongside widespread transcriptional changes in excitatory and inhibitory neurons. In adulthood, persistent hippocampal network alterations emerged, marked by reduced mid-gamma oscillations and theta-gamma coupling. Our findings establish hippocampal CA3 hyperexcitability as an early driver of epileptogenesis in SCN2A -DEE and highlight it as a potential therapeutic target to mitigate disease progression.
Open AccessEarly postnatal CA3 hyperexcitability drives hippocampal development and epileptogenesis in SCN2A developmental and epileptic encephalopathy
Developmental and epileptic encephalopathies caused by pathogenic variants in SCN2A ( SCN2A -DEE), encoding the voltage-gated sodium channel Na v 1.2, present with early-life seizures, developmental delay, and increased mortality. Using a novel Scn2a p.A263V gain-of-function (GOF) mouse model, we demonstrate gene-dose and background-dependent phenotypes ranging from self-limited neonatal seizures to chronic epilepsy with high mortality. In vivo electrophysiology revealed hippocampal seizures as early as postnatal day 2.5, with CA3-driven gamma oscillations preceding seizure onset. CA3 and CA1 pyramidal neurons exhibited transient hyperexcitability during early postnatal development, resolving by P24-30. Single-cell RNA sequencing uncovered gene dose-dependent accelerated maturation of hippocampal networks, peaking at P7, alongside widespread transcriptional changes in excitatory and inhibitory neurons. In adulthood, persistent hippocampal network alterations emerged, marked by reduced mid-gamma oscillations and theta-gamma coupling. Our findings establish hippocampal CA3 hyperexcitability as an early driver of epileptogenesis in SCN2A -DEE and highlight it as a potential therapeutic target to mitigate disease progression.
- Open Access
- 28 September 2022
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 8  (5) , e200020
Efficacy, Tolerability, and Retention of Antiseizure Medications in PRRT2 -Associated Infantile Epilepsy
Background and Objectives Pathogenic variants in PRRT2, encoding for the proline-rich transmembrane protein 2, were identified as the main cause of self-limiting sporadic and familial infantile epilepsy. Reported data on treatment response to antiseizure medications (ASMs) in defined monogenic epilepsies are limited. The aim of this study was to evaluate the treatment response of ASMs in children with monogenic PRRT2-associated infantile epilepsy. Methods A multicenter, retrospective, cross-sectional cohort study was conducted according to the Strengthening the Reporting of Observational Studies in Epidemiology criteria. Inclusion criteria were occurrence of infantile seizures and genetic diagnosis of likely pathogenic/pathogenic PRRT2 variants. Results Treatment response data from 52 individuals with PRRT2-associated infantile epilepsy with a total of 79 treatments (defined as each use of an ASM in an individual) were analyzed. Ninety-six percent (50/52) of all individuals received ASMs. Levetiracetam (LEV), oxcarbazepine (OXC), valproate (VPA), and phenobarbital (PB) were most frequently administered. Sodium channel blockers were used in 22 individuals and resulted in seizure freedom in all but 1 child, who showed a reduction of more than 50% in seizure frequency. By contrast, treatment with LEV was associated with worsening of seizure activity in 2/25 (8%) treatments and no effect in 10/25 (40%) of treatments. LEV was rated significantly less effective also compared with VPA and PB. The retention rate for LEV was significantly lower compared with all aforementioned ASMs. No severe adverse events were reported, and no discontinuation of treatment was reported because of side effects. Discussion In conclusion, a favorable effect of most ASMs, especially sodium channel blockers such as carbamezepine and OXC, was observed, whereas the efficacy and the retention rate of LEV was lower in PRRT2-associated childhood epilepsy. Tolerability in these young children was good for all ASMs reported in the cohort. Classification of Evidence This study provides Class IV evidence that in individuals with PRRT2-associated infantile epilepsy, sodium channel blockers are associated with reduced seizure frequency but levetiracetam is not.
- 28 September 2022
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 8  (5) , e200020
Open AccessEfficacy, Tolerability, and Retention of Antiseizure Medications in PRRT2 -Associated Infantile Epilepsy
Background and Objectives Pathogenic variants in PRRT2, encoding for the proline-rich transmembrane protein 2, were identified as the main cause of self-limiting sporadic and familial infantile epilepsy. Reported data on treatment response to antiseizure medications (ASMs) in defined monogenic epilepsies are limited. The aim of this study was to evaluate the treatment response of ASMs in children with monogenic PRRT2-associated infantile epilepsy. Methods A multicenter, retrospective, cross-sectional cohort study was conducted according to the Strengthening the Reporting of Observational Studies in Epidemiology criteria. Inclusion criteria were occurrence of infantile seizures and genetic diagnosis of likely pathogenic/pathogenic PRRT2 variants. Results Treatment response data from 52 individuals with PRRT2-associated infantile epilepsy with a total of 79 treatments (defined as each use of an ASM in an individual) were analyzed. Ninety-six percent (50/52) of all individuals received ASMs. Levetiracetam (LEV), oxcarbazepine (OXC), valproate (VPA), and phenobarbital (PB) were most frequently administered. Sodium channel blockers were used in 22 individuals and resulted in seizure freedom in all but 1 child, who showed a reduction of more than 50% in seizure frequency. By contrast, treatment with LEV was associated with worsening of seizure activity in 2/25 (8%) treatments and no effect in 10/25 (40%) of treatments. LEV was rated significantly less effective also compared with VPA and PB. The retention rate for LEV was significantly lower compared with all aforementioned ASMs. No severe adverse events were reported, and no discontinuation of treatment was reported because of side effects. Discussion In conclusion, a favorable effect of most ASMs, especially sodium channel blockers such as carbamezepine and OXC, was observed, whereas the efficacy and the retention rate of LEV was lower in PRRT2-associated childhood epilepsy. Tolerability in these young children was good for all ASMs reported in the cohort. Classification of Evidence This study provides Class IV evidence that in individuals with PRRT2-associated infantile epilepsy, sodium channel blockers are associated with reduced seizure frequency but levetiracetam is not.
- Open Access
Aseptic Meningitis, Mucocutaneous Lesions and Arthritis after COVID-19 Vaccination in a 15-Year-Old Boy
We report a 15-year-old boy who developed aseptic meningitis 10 days after administration of the second dose of the COVID-19 vaccine BNT162b2. Although accompanying aphthous mouth ulcers resembling herpetic stomatitis initially led us to suspect an underlying viral infection, broad virological and microbiological screening did not identify any causative pathogen. Gonarthritis and skin lesions, which both developed within three days after admission, extended the clinical presentation eventually resembling an acute Behçetâs disease episode. This is the first description of a juvenile patient with aseptic and pathogen-negative meningitis occurring in close temporal association with vaccination against COVID-19, along with a few previously reported adult patients with isolated meningitis and a further case with meningitis and an accompanying Behçetâs disease-like multisystem inflammation episode as seen in our patient. With billions of individuals being vaccinated worldwide so far and only a few cases of aseptic pathogen-negative meningitis reported in close temporal relation, causality is unclear. However, aseptic meningitis should be kept in mind in the differential diagnosis of patients with persistent or delayed onset of headache and fever following COVID-19 vaccination.
Open AccessAseptic Meningitis, Mucocutaneous Lesions and Arthritis after COVID-19 Vaccination in a 15-Year-Old Boy
We report a 15-year-old boy who developed aseptic meningitis 10 days after administration of the second dose of the COVID-19 vaccine BNT162b2. Although accompanying aphthous mouth ulcers resembling herpetic stomatitis initially led us to suspect an underlying viral infection, broad virological and microbiological screening did not identify any causative pathogen. Gonarthritis and skin lesions, which both developed within three days after admission, extended the clinical presentation eventually resembling an acute Behçetâs disease episode. This is the first description of a juvenile patient with aseptic and pathogen-negative meningitis occurring in close temporal association with vaccination against COVID-19, along with a few previously reported adult patients with isolated meningitis and a further case with meningitis and an accompanying Behçetâs disease-like multisystem inflammation episode as seen in our patient. With billions of individuals being vaccinated worldwide so far and only a few cases of aseptic pathogen-negative meningitis reported in close temporal relation, causality is unclear. However, aseptic meningitis should be kept in mind in the differential diagnosis of patients with persistent or delayed onset of headache and fever following COVID-19 vaccination.
- 1 January 2022
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 36, 7-13
The phenotypic spectrum of PCDH12 associated disorders - Five new cases and review of the literature
- 1 January 2022
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 36, 7-13
The phenotypic spectrum of PCDH12 associated disorders - Five new cases and review of the literature
- 28 October 2021
- Published by Georg Thieme Verlag KG
- Vol. 52  (S 01) , P2.23
The Phenotypic Spectrum of PCDH12-Associated Disorders: Five New Cases and Review of the Literature
Background: PCDH12 is a member of the non-clustered protocadherin family of calcium-dependent cell adhesion proteins, which are involved in the regulation of brain development and endothelial adhesion. To date, only 15 families have been reported with PCDH12-associated disease. Methods: In this study, we reviewed the literature and report the clinical course, imaging data, and the genetic findings of three pediatric and two adult patients with homozygous truncating mutations in PCDH12. Possible systemic activation of type I interferon was assessed by expression analysis of interferon-stimulated genes in peripheral blood lymphocytes of the pediatric cases. Results: We present a comprehensive overview on the clinical spectrum associated with PCDH12 deficiency highlighting the main features such as developmental delay, movement disorder, epilepsy, microcephaly, visual impairment, midbrain malformations, and intracranial calcifications. In addition, we report novel clinical features such as late-onset epilepsy, episodes of transient developmental regression, and dysplasia of the medulla oblongata associated with novel truncating PCDH12 mutations in five cases, three children, and two adults. Interestingly, our data suggests a clinical overlap with interferonopathies. The interferon score was elevated in two of the pediatric patients. Conclusion: This case series expands the genetic and phenotypic spectrum of PCDH12-associated diseases and highlights the broad clinical variability. Interferon activation should be considered as part of the pathomechanism in PCDH12-related disease. *These are the shared first authors. Publication Date: 28 October 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG RĂŒdigerstraĂe 14, 70469 Stuttgart, Germany
- 28 October 2021
- Published by Georg Thieme Verlag KG
- Vol. 52  (S 01) , P2.23
The Phenotypic Spectrum of PCDH12-Associated Disorders: Five New Cases and Review of the Literature
Background: PCDH12 is a member of the non-clustered protocadherin family of calcium-dependent cell adhesion proteins, which are involved in the regulation of brain development and endothelial adhesion. To date, only 15 families have been reported with PCDH12-associated disease. Methods: In this study, we reviewed the literature and report the clinical course, imaging data, and the genetic findings of three pediatric and two adult patients with homozygous truncating mutations in PCDH12. Possible systemic activation of type I interferon was assessed by expression analysis of interferon-stimulated genes in peripheral blood lymphocytes of the pediatric cases. Results: We present a comprehensive overview on the clinical spectrum associated with PCDH12 deficiency highlighting the main features such as developmental delay, movement disorder, epilepsy, microcephaly, visual impairment, midbrain malformations, and intracranial calcifications. In addition, we report novel clinical features such as late-onset epilepsy, episodes of transient developmental regression, and dysplasia of the medulla oblongata associated with novel truncating PCDH12 mutations in five cases, three children, and two adults. Interestingly, our data suggests a clinical overlap with interferonopathies. The interferon score was elevated in two of the pediatric patients. Conclusion: This case series expands the genetic and phenotypic spectrum of PCDH12-associated diseases and highlights the broad clinical variability. Interferon activation should be considered as part of the pathomechanism in PCDH12-related disease. *These are the shared first authors. Publication Date: 28 October 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG RĂŒdigerstraĂe 14, 70469 Stuttgart, Germany
- Open Access
- 16 March 2021
- Published by Wolters Kluwer Health in Neurology
- Vol. 96  (11) , e1539-e1550
RHOBTB2 Mutations Expand the Phenotypic Spectrum of Alternating Hemiplegia of Childhood
Objective To explore the phenotypic spectrum of RHOBTB2-related disorders and specifically to determine whether patients fulfill criteria for alternating hemiplegia of childhood (AHC), we report the clinical features of 11 affected individuals. Methods Individuals with RHOBTB2-related disorders were identified through a movement disorder clinic at a specialist pediatric center, with additional cases identified through collaboration with other centers internationally. Clinical data were acquired through retrospective case-note review. Results Eleven affected patients were identified. All had heterozygous missense variants involving exon 9 of RHOBTB2, confirmed as de novo in 9 cases. All had a complex motor phenotype, including at least 2 different kinds of movement disorder, e.g., ataxia and dystonia. Many patients demonstrated several features fulfilling the criteria for AHC: 10 patients had a movement disorder including paroxysmal elements, and 8 experienced hemiplegic episodes. In contrast to classic AHC, commonly caused by mutations in ATP1A3, these events were reported later only in RHOBTB2 mutationâpositive patients from 20 months of age. Seven patients had epilepsy, but of these, 4 patients achieved seizure freedom. All patients had intellectual disability, usually moderate to severe. Other features include episodes of marked skin color change and gastrointestinal symptoms, each in 4 patients. Conclusion Although heterozygous RHOBTB2 mutations were originally described in early infantile epileptic encephalopathy type 64, our study confirms that they account for a more expansive clinical phenotype, including a complex polymorphic movement disorder with paroxysmal elements resembling AHC. RHOBTB2 testing should therefore be considered in patients with an AHC-like phenotype, particularly those negative for ATPA1A3 mutations.
- 16 March 2021
- Published by Wolters Kluwer Health in Neurology
- Vol. 96  (11) , e1539-e1550
Open AccessRHOBTB2 Mutations Expand the Phenotypic Spectrum of Alternating Hemiplegia of Childhood
Objective To explore the phenotypic spectrum of RHOBTB2-related disorders and specifically to determine whether patients fulfill criteria for alternating hemiplegia of childhood (AHC), we report the clinical features of 11 affected individuals. Methods Individuals with RHOBTB2-related disorders were identified through a movement disorder clinic at a specialist pediatric center, with additional cases identified through collaboration with other centers internationally. Clinical data were acquired through retrospective case-note review. Results Eleven affected patients were identified. All had heterozygous missense variants involving exon 9 of RHOBTB2, confirmed as de novo in 9 cases. All had a complex motor phenotype, including at least 2 different kinds of movement disorder, e.g., ataxia and dystonia. Many patients demonstrated several features fulfilling the criteria for AHC: 10 patients had a movement disorder including paroxysmal elements, and 8 experienced hemiplegic episodes. In contrast to classic AHC, commonly caused by mutations in ATP1A3, these events were reported later only in RHOBTB2 mutationâpositive patients from 20 months of age. Seven patients had epilepsy, but of these, 4 patients achieved seizure freedom. All patients had intellectual disability, usually moderate to severe. Other features include episodes of marked skin color change and gastrointestinal symptoms, each in 4 patients. Conclusion Although heterozygous RHOBTB2 mutations were originally described in early infantile epileptic encephalopathy type 64, our study confirms that they account for a more expansive clinical phenotype, including a complex polymorphic movement disorder with paroxysmal elements resembling AHC. RHOBTB2 testing should therefore be considered in patients with an AHC-like phenotype, particularly those negative for ATPA1A3 mutations.
- Open Access
- 28 October 2020
- Published by MDPI AG in Biomedicines
- Vol. 8  (11) , 456
The Phenotypic Spectrum of PRRT2-Associated Paroxysmal Neurologic Disorders in Childhood
Pathogenic variants in PRRT2, encoding the proline-rich transmembrane protein 2, have been associated with an evolving spectrum of paroxysmal neurologic disorders. Based on a cohort of children with PRRT2-related infantile epilepsy, this study aimed at delineating the broad clinical spectrum of PRRT2-associated phenotypes in these children and their relatives. Only a few recent larger cohort studies are on record and findings from single reports were not confirmed so far. We collected detailed genetic and phenotypic data of 40 previously unreported patients from 36 families. All patients had benign infantile epilepsy and harbored pathogenic variants in PRRT2 (core cohort). Clinical data of 62 family members were included, comprising a cohort of 102 individuals (extended cohort) with PRRT2-associated neurological disease. Additional phenotypes in the cohort of patients with benign sporadic and familial infantile epilepsy consist of movement disorders with paroxysmal kinesigenic dyskinesia in six patients, infantile-onset movement disorders in 2 of 40 individuals, and episodic ataxia after mild head trauma in one girl with bi-allelic variants in PRRT2. The same girl displayed a focal cortical dysplasia upon brain imaging. Familial hemiplegic migraine and migraine with aura were reported in nine families. A single individual developed epilepsy with continuous spikes and waves during sleep. In addition to known variants, we report the novel variant c.843G>T, p.(Trp281Cys) that co-segregated with benign infantile epilepsy and migraine in one family. Our study highlights the variability of clinical presentations of patients harboring pathogenic PRRT2 variants and expands the associated phenotypic spectrum.
- 28 October 2020
- Published by MDPI AG in Biomedicines
- Vol. 8  (11) , 456
Open AccessThe Phenotypic Spectrum of PRRT2-Associated Paroxysmal Neurologic Disorders in Childhood
Pathogenic variants in PRRT2, encoding the proline-rich transmembrane protein 2, have been associated with an evolving spectrum of paroxysmal neurologic disorders. Based on a cohort of children with PRRT2-related infantile epilepsy, this study aimed at delineating the broad clinical spectrum of PRRT2-associated phenotypes in these children and their relatives. Only a few recent larger cohort studies are on record and findings from single reports were not confirmed so far. We collected detailed genetic and phenotypic data of 40 previously unreported patients from 36 families. All patients had benign infantile epilepsy and harbored pathogenic variants in PRRT2 (core cohort). Clinical data of 62 family members were included, comprising a cohort of 102 individuals (extended cohort) with PRRT2-associated neurological disease. Additional phenotypes in the cohort of patients with benign sporadic and familial infantile epilepsy consist of movement disorders with paroxysmal kinesigenic dyskinesia in six patients, infantile-onset movement disorders in 2 of 40 individuals, and episodic ataxia after mild head trauma in one girl with bi-allelic variants in PRRT2. The same girl displayed a focal cortical dysplasia upon brain imaging. Familial hemiplegic migraine and migraine with aura were reported in nine families. A single individual developed epilepsy with continuous spikes and waves during sleep. In addition to known variants, we report the novel variant c.843G>T, p.(Trp281Cys) that co-segregated with benign infantile epilepsy and migraine in one family. Our study highlights the variability of clinical presentations of patients harboring pathogenic PRRT2 variants and expands the associated phenotypic spectrum.